Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Antibody crawled time : 01:00 save search
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
Published: 2023-12-11 (Crawled : 01:00) - prnewswire.com
MEDE | $0.51 0% 500
|
n/a
| Email alert
Add to watchlist
antibody biotech collaboration
Custom Antibody Market Report 2023: Rising Therapeutic Applications for MABs Presents Opportunities
Published: 2023-03-14 (Crawled : 01:00) - prnewswire.com
ABCM | News | $23.99 0.0% 7.4M
|
Health Technology
|
| O: 0.27%
H: 1.07%
C: -3.74%
report antibody market
EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN
Published: 2023-01-16 (Crawled : 01:00) - prnewswire.com
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
| Email alert
Add to watchlist
lecanemab disease alzheimer's japan antibody application authorization anti-amyloid beta
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
Published: 2022-08-24 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.43%
H: 1.39%
C: 0.76%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.16%
H: 0.56%
C: -0.19%
ibi363 australia antibody study phase 1
Innovent Presents Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ibi110 antibody
Innovent Will Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.88%
H: 0.51%
C: -0.15%
ibi110 trials antibody
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
Published: 2022-04-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.36%
H: 0.24%
C: -0.62%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.52%
H: 1.58%
C: 0.22%
ibi310 treatment cancer designation antibody
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published: 2022-04-11 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.82%
H: 0.59%
C: -1.88%
ibi322 results antibody phase 1
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-03-29 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.13%
H: 0.38%
C: -1.25%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.05%
H: 1.43%
C: 1.01%
ibi389 trial antibody phase 1
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-23 (Crawled : 01:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.59%
H: 0.89%
C: -0.93%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.87%
H: 0.84%
C: -1.12%
cd73 trial phase 1 antibody phase 1b
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published: 2022-02-24 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -1.25%
H: 1.21%
C: 1.04%
cd73 trial phase 1 antibody phase 1b
Innovent Announces Two Registration Studies of IBI306 (anti-PCSK-9 antibody) Met Primary Endpoint
Published: 2022-02-17 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -1.88%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: -0.72%
H: 2.03%
C: 0.73%
ibi306 antibody
WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
Published: 2021-12-28 (Crawled : 01:00) - prnewswire.com
SRNE | $0.015 -8.85% 56K
|
Health Technology
|
| O: -1.26%
H: 1.45%
C: -10.73%
cd47 antibody
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma
Published: 2021-12-13 (Crawled : 01:00) - prnewswire.com
GNMSF | News | $290.34 3.83% 340
|
Health Technology
|
| O: -3.62%
H: 5.16%
C: 4.16%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 1.9%
H: 0.0%
C: 0.0%
GMAB | News | $28.47 -0.32% -0.32% 460K
|
Health Technology
|
| O: -4.01%
H: 1.01%
C: -2.07%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.22%
H: 1.65%
C: 1.15%
treatment antibody
iTeos Announces New Data for its Anti-TIGIT Antibody, EOS-448, at the American Society of Hematology Annual Meeting and TIGIT Therapies Digital Summit 2021
Published: 2021-12-09 (Crawled : 01:00) - biospace.com/
ITOS | $10.58 -3.73% -3.88% 150K
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
eos-448 ema antibody
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications
Published: 2021-11-08 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.59%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 1.38%
H: 0.98%
C: -2.62%
results communication antibody communications preclinical pre-clinical
Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002
Published: 2021-09-27 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -1.21%
H: 0.47%
C: -1.55%
antibody clearance
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
phase 1 antibody phase 2
SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test
Published: 2021-07-16 (Crawled : 01:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
covid test antibody distribution diagnostics covid-19 diagnostic
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published: 2021-07-12 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.98%
H: 1.2%
C: 0.36%
phase 1 antibody phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.